Dear families, dear colleagues,

We welcome you on our website for the Cancer Predisposition Syndrome Registry. Cancer predisposition syndromes (CPS) are genetic conditions associated with an increased cancer risk. CPS are especially relevant for children and adolescents with cancer. We are a team of scientists and pediatric oncologists. It is our aim to advance CPS research, together with affected individuals and their families other scientists and health professionals: through Facts, Investigation, and Therapy.

Here on our website, we concisely review CPS relevant for children, including the medical background and therapeutic measures, for families affected by a CPS and for health professionals. You will also find links to support groups and relevant articles.

We would like to learn more about the cancer risks in individuals affected by a CPS and about the biology underlying cancer development in these patients. We also would like to collect data on the benefit of cancer surveillance. Therefore, we have launched a CPS registry.

We are just beginning to understand the urgent need of better cancer therapies for individuals with CPS. Therefore, it is important to further advance cancer therapies for CPS patients. We are promoting this process though our own research and by collaborating with the various childhood cancer study groups of the Society of Pediatric Oncology and Hematology.

We are just beginning to understand the important role of CPS, especially in children affected by cancer. We would like to accelerate this process. In case you have questions related to CPS or if you wish to support our work, we are looking forward to receiving your message!

Christian P. Kratz, MD                                   Stefan M. Pfister, MD

Our research projects

Genetic cancer predisposition is the most important known cause of childhood cancer. By launching the CPS-Registry, we would like to

  • define the cancer risks associated with CPS

  • investigate the mechanisms of cancer development in CPS patients

  • examine, if cancer surveillance improves the health of affected individuals.

We please you to support our work by reporting your patients to our registries as a treating physician. The CPS registry is open for all known cancer predisposition syndromes. Both children and adults can be registered.

Summary of the most established CPS

– in lay terms –

for patients and their families

Summary of the most established CPS

– scientific and detailed –

for scientists and health professionals

CPS Navigator –
from tumor to associated CPS

– diagnostic tool –

for physicians treating cancer patients

About us – our teams in Hannover and Heidelberg


Our team in Hannover is a multidisciplinary group of motivated pediatric oncologists and scientists working on the multiple medical and scientific aspects of CPS. We aim at collecting information on the mechanisms of cancer development and the cancer epidemiology and to improve the therapies for and outcomes of individuals affected by these conditions.


The „Hopp Children’s Cancer Center at NCT Heidelberg (KiTZ)“ was founded, in order to create new ways to diagnose and treat children with cancer and in order to work towards a more precise medicine for children with cancer. Stefan Pfister directs the preclinical program. His research has substantially contributed to the current understanding on how germline genetic factors contribute to cancer, especially in children with brain tumors.

News about our scientific work

Start of the “Liquid Biopsy” project

27. January 2020|

Based on the Cancer Predisposition Syndrome Registry, the Liquid Biopsy project is now starting. The aim is to detect small DNA fragments of tumor cells in the blood. In the future, this will enable the early and least invasive detection of the development and process of malignant diseases.

Integration of FAR01 in LFS-CPS-R01

21. November 2019|

The Fanconi Anaemia Registry has been affiliated to the Cancer Predisposition Syndrome Registry since January 2020. This has significantly simplified the administrative structures. However, this does not change anything for the registered patients. A click on the picture above will take you to further information about the affiliation.

Competence in clinic and science

CPS-Outpatient clinic

If you or your child has been diagnosed with a cancer predisposition syndrome (CPS), you are welcome to come to our CPS-Outpatient clinic; especially if such an offer is not available in your area. Please ask your attending physicians in this regard.
To make an appointment with us, simply fill out the registration form and send it to us. We will contact you as soon as possible.

Registration at the CPS-Outpatient clinic

Department of Paediatric Haematology and Oncology
Hannover Medical School
D-30625 Hannover, Germany
+49 511 532-9037 (on workdays from 12 o’clock)
+49 511 532-8766
Due to the Corona crisis we can currently only offer limited dates. We thank you for your understanding!
Contact form (german language)
Simply download and fill out digitally. If you are unable to print out the form, please contact us at the number given above.


Since 2017 we have been conducting the Registry for people with CPS. We are investigating questions relating to the development of cancer and asserving biospecimen. In this way, we create a resource that allows us to answer basic scientific questions. All information about our CPS-Registry, the Fanconi Anemia Registry and the two accompanying projects “Liquid Biopsy” and “ADDRess” can be found under the following links.

Further information

Department of Paediatric Haematology and Oncology
Hannover Medical School
D-30625 Hannover, Germany
+49 511 532-9408 oder -6738
+49 511 532-161026
Due to the Corona crisis, you can best contact us by e-mail. Thank you for your understanding!

Recent Publications on CPS


“Mesenchymal Hamartoma of Liver and DICER1 Syndrome”

In this article, published in "The New England Journal of Medicine", a mesenchymal hematoma of the liver (MHL) was discovered in two children with DICER1 syndrome. MHL is a benign tumor in children that is characterized by, among other things, cystically dilated bile ducts. The data of this study suggest that MHL is a new phenotype of DICER1 syndrome. For further information click on the publication title.


XAF1 as a modifier of p53 function and cancer susceptibility”

This article was published in the journal “SCIENCE ADVANCE” and reports on a newly discovered “modifier” of the p53 function of a variant and its possible influence on the cancer susceptibility of those affected. Please click on the publication title for more information.

Go to Top